Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Heska Corp. The ANADA provides for use of chewable tablets containing ivermectin and pyrantel pamoate for prevention of heartworm disease and for treatment and control of certain gastrointestinal parasites in dogs.
This rule is effective September 29, 2003.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Lonnie W. Luther, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-8549, e-mail: firstname.lastname@example.org.End Further Info End Preamble Start Supplemental Information
Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO 80525, filed ANADA 200-338 that provides for veterinary prescription use of TRI-HEART PLUS (ivermectin and pyrantel pamoate) Chewable Tablets for prevention of canine heartworm disease caused by Dirofilaria immitis and for treatment and control of ascarids (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, A. braziliense, and Uncinaria stenocephala) in dogs. Heska Corp.'s TRI-HEART PLUS Chewable Tablets is approved as a Start Printed Page 55823generic copy of Merial's HEARTGARD Plus Chewables, approved under NADA 140-971. ANADA 200-338 is approved as of August 13, 2003, and 21 CFR 520.1196 is amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.
In addition, Heska Corp. is not currently listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for the firm.
In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.Start List of Subjects
List of Subjects
- Administrative practice and procedure
- Animal drugs
- Reporting and recordkeeping requirements
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,End Amendment Part Start Part
PART 510—NEW ANIMAL DRUGSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part Start Amendment Part
2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding a new entry for “Heska Corp.” and in the table in paragraph (c)(2) by numerically adding a new entry for “063604” to read as follows:End Amendment Part
(c) * * *
(1) * * *
|Firm name and address||Drug labeler code|
|* * * * *|
|Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO 80525||063604|
|* * * * *|
(2) * * *
|Drug labeler code||Firm name and address|
|* * * * *|
|063604||Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO 80525|
|* * * * *|
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGSEnd Part Start Amendment Part
3. The authority citation forEnd Amendment Part Start Amendment Part
4. Section 520.1196 is amended by revising paragraph (b) to read as follows:End Amendment Part
(b) Sponsors. See Nos. 050604, 051311, and 063604 in § 510.600(c) of this chapter.
Dated: September 15, 2003.
Deputy Director, Center for Veterinary Medicine.
[FR Doc. 03-24496 Filed 9-26-03; 8:45 am]
BILLING CODE 4160-01-S